Literature DB >> 23286278

Predicting onset of major depression in general practice attendees in Europe: extending the application of the predictD risk algorithm from 12 to 24 months.

M King1, C Bottomley, J Bellón-Saameño, F Torres-Gonzalez, I Svab, D Rotar, M Xavier, I Nazareth.   

Abstract

BACKGROUND: PredictD is a risk algorithm that was developed to predict risk of onset of major depression over 12 months in general practice attendees in Europe and validated in a similar population in Chile. It was the first risk algorithm to be developed in the field of mental disorders. Our objective was to extend predictD as an algorithm to detect people at risk of major depression over 24 months. Method Participants were 4190 adult attendees to general practices in the UK, Spain, Slovenia and Portugal, who were not depressed at baseline and were followed up for 24 months. The original predictD risk algorithm for onset of DSM-IV major depression had already been developed in data arising from the first 12 months of follow-up. In this analysis we fitted predictD to the longer period of follow-up, first by examining only the second year (12-24 months) and then the whole period of follow-up (0-24 months).
RESULTS: The instrument performed well for prediction of major depression from 12 to 24 months [c-index 0.728, 95% confidence interval (CI) 0.675-0.781], or over the whole 24 months (c-index 0.783, 95% CI 0.757-0.809).
CONCLUSIONS: The predictD risk algorithm for major depression is accurate over 24 months, extending it current use of prediction over 12 months. This strengthens its use in prevention efforts in general medical settings.

Entities:  

Mesh:

Year:  2013        PMID: 23286278     DOI: 10.1017/S0033291712002693

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  7 in total

1.  Developing algorithms to predict adult onset internalizing disorders: An ensemble learning approach.

Authors:  Anthony J Rosellini; Siyu Liu; Grace N Anderson; Sophia Sbi; Esther S Tung; Evdokia Knyazhanskaya
Journal:  J Psychiatr Res       Date:  2019-12-06       Impact factor: 4.791

Review 2.  Prognosis and improved outcomes in major depression: a review.

Authors:  Christoph Kraus; Bashkim Kadriu; Rupert Lanzenberger; Carlos A Zarate; Siegfried Kasper
Journal:  Transl Psychiatry       Date:  2019-04-03       Impact factor: 6.222

3.  Risk of Depression, Anxiety, and Stress During the Second Wave of COVID-19 in Slovenia.

Authors:  Polona Rus Prelog; Teodora Matić; Peter Pregelj; Aleksander Sadikov
Journal:  Front Psychiatry       Date:  2022-01-12       Impact factor: 4.157

4.  Predicting the presence of depressive symptoms in the HIV-HCV co-infected population in Canada using supervised machine learning.

Authors:  Gayatri Marathe; Erica E M Moodie; Marie-Josée Brouillette; Joseph Cox; Curtis Cooper; Charlotte Lanièce Delaunay; Brian Conway; Mark Hull; Valérie Martel-Laferrière; Marie-Louise Vachon; Sharon Walmsley; Alexander Wong; Marina B Klein
Journal:  BMC Med Res Methodol       Date:  2022-08-12       Impact factor: 4.612

Review 5.  Learning and behavioral deficits associated with the absence of the fragile X mental retardation protein: what a fly and mouse model can teach us.

Authors:  Ana Rita Santos; Alexandros K Kanellopoulos; Claudia Bagni
Journal:  Learn Mem       Date:  2014-09-16       Impact factor: 2.460

6.  External validation of the international risk prediction algorithm for major depressive episode in the US general population: the PredictD-US study.

Authors:  Yeshambel T Nigatu; Yan Liu; JianLi Wang
Journal:  BMC Psychiatry       Date:  2016-07-22       Impact factor: 3.630

7.  Target-D: a stratified individually randomized controlled trial of the diamond clinical prediction tool to triage and target treatment for depressive symptoms in general practice: study protocol for a randomized controlled trial.

Authors:  Jane Gunn; Caroline Wachtler; Susan Fletcher; Sandra Davidson; Cathrine Mihalopoulos; Victoria Palmer; Kelsey Hegarty; Amy Coe; Elizabeth Murray; Christopher Dowrick; Gavin Andrews; Patty Chondros
Journal:  Trials       Date:  2017-07-20       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.